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Abstract 
Pulse oximetry is the most common way to measure a patient’s respiratory status in the hospital setting; however, capnography 
monitoring is a more accurate and sensitive technique which can more comprehensively measure respiratory function.  Due to the 
limited number of capnography monitoring equipment at the University of Minnesota Medical Center-Fairview (UMMC-Fairview), we 
analyzed which patients should preferentially be chosen for capnography monitoring over pulse oximetry based on risk of respiratory 
depression.  We conducted a retrospective chart review of all serious opioid-induced over-sedation events that occurred at UMMC-
Fairview between January 1, 2008 and June 30, 2012.  Thirteen risk factors were identified which predispose patients to respiratory 
depression.  The average patient demonstrated 3.75 risk factors.  The most commonly occurring risk factor was the concomitant use 
of multiple opioids or an opioid and a CNS-active sedative, followed by an ASA score ≥ 3.  Based on this data, we developed a 
scorecard for choosing patients at the most risk of developing respiratory depression; these patients are the best candidates for 
capnography.  Although further studies are necessary to corroborate this research, at this time giving extra consideration to patients 
demonstrating the previously stated risk factors is prudent when assessing those patients most in need of capnography. 
 
 
Introduction 
Pulse oximetry is the current standard of practice for 
monitoring a patient’s respiratory status in the hospital 
setting.  A pulse oximeter sensor is placed on a thin part of a 
patient’s body, usually on a fingertip or earlobe.  It uses a 
light-emitting diode and photo detector to measure changes 
in the wavelength of the light due to absorption by 
oxygenated hemoglobin.  Therefore, it obtains a 
measurement of the percentage of a patient’s hemoglobin 
that is saturated by oxygen molecules
1, 2, 3
.   A healthy person 
should have an arterial oxygen saturation level of 97-99%, 
and anything less than 90% is considered hypoxic
3
.  Pulse 
oximetry has been described as “arguably the most significant 
technological advance ever made in the monitoring of the 
wellbeing and safety of patients during anesthesia, recovery, 
and critical care”
 
as prior to its advent the primary way of 
measuring hypoxemia was assessing the skin for cyanosis
3, 4
.  
 
However, despite the huge medical monitoring advancement 
oximetry has proven to be, it is not perfect, and there have 
been instances when oximeters have failed to alert a nurse 
that a patient was in respiratory distress
4
.  A major 
disadvantage of pulse oximetry is that it only measures 
oxygenation of the arterial blood and therefore can only 
detect hypoxemia
1-5
.  It does not have the capability to 
measure ventilation status or the adequacy of carbon dioxide 
elimination; therefore it is not an all-encompassing tool to 
measure respiratory function
4
.  Additionally, pulse oximetry is 
unable to detect important early indicators of respiratory 
depression such as changes in respiratory rate, pauses in 
breathing, or decreases in exhaled carbon dioxide levels
1
. 
Also, pulse oximeters may give deceptive results under 
certain situations, such as when a patient is receiving 
supplemental oxygen, has weak pulses, has poor perfusion, 
or has a dyshemoglobinemia
1-3, 5
.   
 
The term capnography refers to the monitoring of the partial 
pressure of carbon dioxide during exhalation, and it has been 
shown to be a more reliable way of detecting respiratory 
depression
1, 5
.  Capnography is more sensitive than pulse 
oximetry in detecting respiratory abnormalities, and it can 
more rapidly detect acute changes in respiratory status
5
.  
Unlike a pulse oximeter, capnography monitoring involves 
wearing a nasal cannula.  The cannula contains an infra-red 
light and a sensor, which detects the amount of carbon 
dioxide being exhaled based on changes in the amount of 
infra-red light returning to the sensor. 
 
Capnography monitoring can measure many more 
components of respiration than pulse oximetry. Respiratory 
rate, exhaled carbon dioxide levels, and apneic events or 
pauses in breathing can all be detected by capnography.  
Additionally, the patient can also receive supplemental 
oxygen through the nasal cannula
1
.  Capnography monitoring 
is proactive, as respiratory status is measured in real-time by 
continuously measuring expiratory carbon dioxide.  In 
contrast, pulse oximetery monitoring is more reactive, as it 
only detects hypoxemia, providing an indirect measurement 
of respiratory function
5
. 
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The major downfall of capnography is its invasiveness and 
potentially reduced patient compliance, as some patients 
refuse to wear the nasal cannula.  Additionally, there is a 
potential for capnography failure in patients who have 
severely congested nasal passages or significant deviation of 
the nasal structures.  To bypass this problem, some 
capnography devices contain an attached mouth piece; these 
devices are able to measure the exhaled carbon dioxide via 
the nose and mouth.  Therefore, capnography would still be a 
feasible option for these patients as long as the patient can 
breathe through the mouth.  [Note: the capnography device 
(Oridion Capnostream) used at UMMC-Fairview does contain 
a mouth piece.] 
 
There are several reports in the literature that illustrate the 
superiority of capnography over pulse oximetry.  In a study by 
Hutchison and Rodriguez conducted in post-orthopedic 
surgery patients at risk for developing obstructive sleep 
apnea and receiving opioids, capnography detected 146 
episodes of respiratory depression while pulse oximetry 
detected only six
1.
  Cacho et al. monitored 50 patients 
receiving opioids, benzodiazepines, and/or propofol during 
colonoscopy using pulse oximetry and capnography 
simultaneously and found that pulse oximetry only detected 
38% of the oxygen desaturation episodes detected by 
capnography
5
.  While there is consensus within the medical 
community regarding the superiority of capnography 
compared to pulse oximetry, the use of capnography is still 
limited.  Although its use has recently grown from being used 
to monitor intubated patients under general anesthesia to 
other hospital settings and during emergent situations
5, 6
, 
capnography is still far from being routinely used hospital-
wide.  
 
The main reason the use of capnography is not more 
widespread is due to the fact that there has not been a strong 
consensus on which patients should receive capnography 
monitoring.  The Joint Commission suggested capnography in 
patients receiving opioid analgesics, but has not further 
specified which patients or taken a strong stand on this
7
.  The 
Anesthesia Patient Safety Foundation stated that 
capnography should be used in patients who require 
supplemental oxygen
8
.  As it stands, much of the decision-
making regarding which patients will get capnography 
monitoring and which patients will get pulse oximetry is left 
up to the individual hospitals and health systems, rather than 
being directed by national group or association consensus.   
 
Currently, there is a limited number of capnography 
monitoring equipment  available at the University of 
Minnesota Medical Center-Fairview (UMMC-Fairview), and 
no solid criteria has been established at that institution 
regarding which patients should be monitored with 
capnography and which patients can be safely monitored by 
oximetry.  Therefore, the aim of this research was to develop 
a scorecard for identifying those patients at UMMC-Fairview 
who are at the highest risk for experiencing respiratory 
depression during their hospitalization.  These patients are 
the ideal candidates for capnography monitoring and should 
preferentially be chosen over other patients to receive 
capnography monitoring instead of pulse oximetry 
monitoring. It has been estimated that opioid-induced 
respiratory depression in the hospital setting occurs as 
frequently as one in every 200 patients
7
.  Therefore, a 
retrospective chart review of opioid-induced adverse events 
was conducted to identify the most significant risk factors for 
developing opioid-induced respiratory depression. 
 
Methodology 
This study was approved by the University of Minnesota 
Institutional Review Board (IRB); IRB code number 
1206M16442.  A retrospective chart review was conducted 
for all serious opioid-related over-sedations that occurred 
within UMMC-Fairview hospitals (including both East and 
West banks, but excluding Amplatz Children’s Hospital) from 
January 1, 2008 to June 30, 2012.  Serious adverse events 
were defined as those classified as Category F, G or H 
according to the National Coordinating Council for 
Medication Error Reporting and Prevention (NCC MERP) 
criteria.  Per these criteria, a category F event is defined as an 
error that may have contributed to or resulted in temporary 
harm to the patient and required initial or prolonged 
hospitalization.  A category G event is defined as an error that 
may have contributed to or resulted to in permanent patient 
harm.  A category H event is defined as an error that occurred 
that required intervention necessary to sustain life
9
  
(see Table 1) 
 
Records of adverse events that occurred during this time 
period were accessed through Fairview’s adverse event 
reporting system, I-CARE.  I-CARE is a confidential adverse 
event reporting system.  When a patient at a Fairview 
hospital receives naloxone (an opioid antagonist given during 
suspected or confirmed opioid overdose) an automatic 
trigger alerts the pharmacist.  The pharmacist is then 
required to conduct a patient safety review and report the 
over-sedation event in I-CARE.  
Once the adverse event records meeting the inclusion criteria 
were accessed through I-CARE, the patient involved in the 
adverse event was identified through the I-CARE report.  
Throughout the duration of the study, each patient was solely 
identified by the twelve digit I-CARE event tracking number 
which was assigned to each adverse event upon reporting it 
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to the I-CARE system.  Prior to any data collection, each 
patient’s chart was reviewed to ensure that the patient did 
not object to the use of their medical records for research 
purposes, as designated on the ‘Consent for Services’ form 
filled out by each patient on admission to the hospital.  Once 
consent to use the patient’s medical record was verified and 
documented, the patient’s electronic medical record (EMR) 
and paper chart were reviewed to collect additional data 
surrounding the adverse event. Data collected included the 
following:  
 
1. Opioid(s) the patient was taking that led to the 
adverse event 
2. American Society of Anesthesiologists Physical 
Status Classification System (commonly referred to 
as the ASA score) which is a system of assessing 
patients’ fitness or physical status prior to surgery.  
The categories are
10
: 
a. ASA 1: a normal healthy patient, 
b. ASA 2: a patient with mild systemic disease, 
c. ASA 3: a patient with severe systemic 
disease, 
d. ASA 4: a patient with severe systemic 
disease that is a constant threat to life, 
e. ASA 5: a moribund patient who is not 
expected to survive the operation, 
f. ASA 6: a declared brain-dead patient whose 
organs are being removed for donor 
purposes 
[Note: The ASA score was only included if the patient 
had surgery during the admission during which the 
adverse event occurred.] 
3. Renal or hepatic insufficiency, documented in history 
& physical or other notes from the admission during 
which the adverse event occurred; conditions 
included are hydronephrosis, history of renal 
transplant or heminephrectomy with baseline 
elevated serum creatnine (SCr) (defined as SCr > 1.25 
mg/dL), chronic kidney disease (CKD) from any 
cause, diabetic nephropathy with baseline elevated 
SCr, hepatitis, cirrhosis, end-stage liver disease 
(ESLD) from any cause, and history of liver transplant 
4. Patient age at the time of the adverse event 
5. Use of a patient-controlled analgesia pump (PCA 
pump) 
6. Other central nervous system/sedating medications 
the patient was taking concurrently with the opioid; 
medication classes included in this study are 
benzodiazepines, barbiturates, hypnotics such as ‘Z-
drugs’ (zolpidem, eszopliclone, and zaleplon), and 
first-generation H1 antagonists 
7. Diagnosed lung disease; conditions included are 
asthma, chronic obstructive pulmonary disease 
(COPD), cystic fibrosis (CF), chronic shortness of 
breath, chronic dyspnea on exertion, emphysema, 
history of lung transplant, pulmonary fibrosis, and 
lung cancer 
8. Body mass index (BMI), calculated with the weight 
and height of the patient during the admission 
during which the adverse event occurred 
9. Diagnosed sleep apnea 
10. Diagnosed muscular-skeletal disorder; conditions 
included are multiple sclerosis (MS), Bell’s Palsy, 
chest muscle atrophy, and paralysis 
11. Unstable post-anesthesia care unit (PACU) transfer, 
which was defined as any patient requiring 
supplemental oxygen upon transfer out of the PACU 
12. High opioid dose; defined as: 
a. Fentanyl patch dose > 50mcg/hr 
b. Methadone use 
c. IV hydromorphone dose ≥ 1mg or 
equivalent 
d. Long-acting opioid formulations with a total 
daily dose > 30mg oral morphine or 
equivalent  
e. Long-acting opioid formulations with as 
needed (PRN) instructions or dosage ranges 
Note: all equivalent doses calculated based on 
standard accepted opioid conversions
11
 
13. PCA pumps with a basal rate being used in a opioid-
naïve patient (opioid naïve being defined as daily 
total oral morphine dose < 30mg or equivalent
11
) 
14. Dose stacking, defined as rapid subsequent 
administration of multiple doses of medications  
The above criteria were chosen as data collection points 
based on risk factors for respiratory depression as reported in 
the literature
7, 8, 12-16
.  In addition, data such as renal and 
hepatic function, dose stacking, and ASA score were collected 
based on input from the multi-disciplinary work group 
involved in the implementation of the widespread use of 
capnography throughout the hospital.  Cut-offs for ASA score 
and age to be considered a risk factor were determined to be 
ASA score ≥ 3 and age ≥ 65 years.  Obesity was defined as a 
BMI ≥ 35. 
 
Results 
During the study period, 49 serious opioid-related adverse 
events occurred, of which 40 were included in the study.  
There were 30 category F events, zero category G events, and 
19 category H events.  Of these 49 events, nine 
patients/events were excluded due to patients not 
Student Project PRACTICE-BASED RESEARCH 
 
http://z.umn.edu/INNOVATIONS                  2013, Vol. 4, No. 3, Article 128                               INNOVATIONS in pharmacy   4 
 
consenting to the use of their medical records for research 
purposes (n=3) and inability to locate the patient’s paper 
charts or an incomplete EMR due to a system outage during 
the time that the adverse event occurred (n=6). 
Table 2 displays the breakdown of each risk factor with the 
associated number and percentage of patients with each risk 
factor.  Even though the total study population was 40 
patients, not all patients were able to be assessed for all risk 
factors.  Due to incomplete medical records, BMI information 
and all medication administration records could not be 
collected for all patients.  Additionally, ASA score was not 
calculated for patients who did not undergo a surgery during 
their hospitalization, and PCA use in the opioid naïve could 
only be determined for patients on PCAs.  Therefore, the total 
number of patients assessed for each condition is also noted 
in the table. 
In almost 90% of all patients who experienced an opioid-
induced over-sedation, the patient was on multiple sedating 
medications, including multiple opioids.  Three out of four 
patients studied had an ASA score greater than 3.  
Approximately one-third of patients exhibited the risk factors 
of high opioid dose, PCA use, diagnosed lung disease, renal or 
hepatic dysfunction, dose stacking, age ≥ 65, PCA with a basal 
rate used in an opioid naïve patient, and BMI ≥ 35.  
Diagnosed sleep apnea, muscular disorder, and unstable 
PACU transfer were rarely-seen risk factors, occurring in 
12.5% or less of the study population. 
 
Of the 13 risk factors listed above, all but one patient in the 
study displayed multiple risk factors.  Most patients had a 
sum total of four risk factors for respiratory depression 
(n=11), followed by three risk factors (n=9), two risk factors 
(n=8), five risk factors (n=5), six risk factors (n=5), one risk 
factor (n=1), and seven risk factors (n=1).  No patients in this 
study had zero risk factors or greater than seven risk factors.  
The distribution of the number of risk factors was noted to 
fall in a bell-shaped curve with the average patient having a 
total of 3.75 risk factors.  Both the median and mode were 4 
risk factors. 
 
The majority of patients who experienced an opioid-induced 
adverse event were taking one opioid concurrently (n=21), 
followed by two concurrent opioids (n=15), and three 
concurrent opioids (n=4).  The most commonly implicated 
opioid was fentanyl IV boluses, followed by hydromorphone 
PCAs and hydromorphone IV boluses.  The majority of the 
CNS-active/sedating medications used concurrently with 
opioids in this patient population were benzodiazepines 
followed by first generation H1 antagonists (Table 3). There 
are no hospital-wide standing orders that dictate the 
predominant use of fentanyl, which would have helped to 
explain why fentanyl is the most frequently implicated opioid.  
However, at UMMC-Fairview fentanyl is frequently used in 
the operating room and ICU, and is part of the order set for 
procedures such as endoscopy.   
 
Half of our patient population (n=20) had three or four risk 
factors for developing respiratory depression, and the 
average, mean, and median fell within the range of three to 
four risk factors.  Therefore, it was decided to further 
quantify the most common risk factors present in the most 
‘average risk’ (3-4 risk factors) patient.  This provides a 
method for distinguishing the most frequently implicated, 
and hence critical risk factors for respiratory depression 
present in these patients; in other words, a way to ‘tease out’ 
the most important risk factors.  Since the aim of this 
research was to develop a scorecard for assessing those 
patients most at risk for experiencing an opioid-induced over-
sedation, this also helps to limit, focus, and specify the risk 
factors of most concern to consider while developing the 
scorecard. 
 
The results of this analysis are shown in Table 4, which 
describes the associated number and percentage of patients 
with each risk factor.  Eighty-five percent of all three and four 
risk factor patients were taking more than one CNS-active 
sedative medication, including multiple opioids.  Forty-six 
percent of patients had an ASA score ≥ 3, and 45% of patients 
experienced opioid dose stacking.  Forty percent were opioid 
naïve but had a PCA with basal rate.  Approximately one-third 
of ‘average risk’ patients exhibited the risk factors of high 
opioid dose, diagnosed lung disease, and renal or hepatic 
insufficiency.  BMI ≥ 35, PCA use, age ≥ 65, muscular disorder, 
and unstable PACU transfer occurred in one quarter or less of 
the ‘average risk’ patient population.  No patients in the 
average risk group had diagnosed sleep apnea. 
The frequency of risk factors in the ‘average risk’ patient 
group was similar to that of the entire study population.  The 
number one and number two risk factors in both groups—
multiple CNS-active sedatives, including multiple opioids and 
ASA score ≥ 3, respectively—were the same between the two 
groups.   The most significant difference between the two 
groups was the frequency of dose stacking, which was 30% in 
the entire study population compared to 45% in the ‘average 
risk’ patients.  
Based on the frequency of multiple risk factors per patient 
and the quantification of the most critical risk factors in all 
and in ‘average risk’ patients, the scorecard was developed  
(Figure 1).  Since ASA ≥ 3 and use of multiple opioids or CNS-
active sedatives were the two most commonly implicated risk 
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factors in the entire study population and the ‘average risk’ 
subset, it was decided these risk factors should be weighted 
more heavily compared to the other risk factors.  Therefore, 
in developing the scorecard, these two risk factors are scored 
as two points (the equivalent of 2 risk factors), while the 
other risk factors are scored as one point.  After calculating 
the sum total of the risk factors—called the ‘risk factor 
equivalent’—if that number is five or greater, the patient 
should be preferentially considered for capnography.  
Unstable PACU transfer and dose stacking were excluded for 
the purpose of developing the scorecard as they are risk 
factors that are not based on patient characteristics or 
medication regimens, but rather are indicative of errors or 
oversights in care that can contribute to opioid-induced 
respiratory depression. 
Discussion 
We examined the most significant risk factors in predicting an 
opioid-induced respiratory depression event in a 
retrospective chart review of patients at UMMC-Fairview.  
We demonstrated that an ASA score ≥ 3 and concomitant use 
of multiple opioids or an opioid and another CNS-active 
sedative are the two most significant risk factors in 
predisposing a patient to this type of adverse event. 
Therefore, these risk factors should be given additional 
consideration when determining a patient’s respiratory 
depression risk. 
The author did not know at the start of the study that the 
data would suggest a ‘risk factor equivalent’ score of 5. The 
decision to use 5 as the cut-off at which capnography should 
be considered was based on several factors.  Primarily, the 
data collected during the study suggested 5 as an appropriate 
cut-off.  As the average patient in our study had 3.75 risk 
factors, patients with five or more ‘risk factor equivalents’ 
were assumed to be a higher risk patient and would be 
considered good candidates for capnography.  Practicality 
was also considered, as the goal of this research was to pare 
down the number and decide the importance of each risk 
factor.  It was crucial to design the scorecard in a way that the 
most at-risk patients can be identified yet limited to a 
manageable number that can realistically be monitored by 
the hospital’s capnography resources.  Therefore, our 
scorecard was constructed with 5 ‘risk factors equivalents’ as 
the cut off.  When our study population was assessed with 
this scorecard, 20 patients (50%) would have met criteria for 
capnography monitoring. 
Our results were somewhat consistent with already 
established guidelines for identifying patients at risk for 
respiratory depression.  The American Society of 
Anesthesiologists Task Force
 
(ASATF) recommends that 
particular attention should be directed toward those with 
obstructive sleep apnea, coexisting disease or conditions 
(e.g., obesity, diabetes), preoperative medications (including 
opioids), high opioid doses, concomitant use of opioids with 
sedatives or hypnotics, and extremes of age when identifying 
at-risk patients
13
.  The Anesthesia Patient Safety Foundation 
(APSF)
 
lists obstructive sleep apnea, obesity, and chronic 
opioid therapy as risk factors of concern
8
.  The Joint 
Commission states sleep apnea, morbid obesity, snoring, old 
age, no recent opioid use, post-surgery, increased opioid 
dose requirement, longer length of time receiving general 
anesthesia during surgery, concomitant use of other sedating 
medications, preexisting pulmonary or cardiac disease, 
smoker, and thoracic surgical incisions as characteristics of 
patients who are at higher risk of respiratory depression
7
.    
Both Joint Commission and ASATF guidelines mention the 
significance of concomitant use of opioids with 
sedatives/hypnotics, a risk factor which was also strongly 
corroborated by the results of this study, as it was our most 
significantly predictive risk factor.  Although no group 
specifically identified a high ASA score as a risk factor, having 
an ASA ≥ 3 indicates the presence of severe systemic disease; 
a patient with a coexisting disease such as obesity or sleep 
apnea (risk factors mentioned in all three sets of guidelines) 
would likely be assigned an ASA score ≥ 3 anyway.  
It is also worth mentioning that some of the risk factors 
examined in this study are modifiable and can be omitted 
with sound judgment from the health care provider.  Dose 
stacking, the practice of rapid and subsequent administration 
of sedating mediations, was implicated in 30% of over-
sedation events in this study.  Nurses need to be cautious 
about using too many sedating medications in a patient in a 
short time span to avoid over-medicating, and should also be 
utilizing non-pharmacological methods to relax and comfort 
patients, such as repositioning or distraction.  Unstable PACU 
transfers were only a contributing factor in 5% of over-
sedation events in this study, but continued, careful 
assessment is necessary prior to patient transfer to assure 
good outcomes.  Finally, one-time bolus dosing, especially 
fentanyl boluses, is common is procedural areas.  Limiting the 
amount of bolus dosing and being cognizant of the 
cumulative amount given in multiple boluses is another 
important safety measure.  While capnography is a sensitive 
tool, too many bolus doses can quickly cause respiratory 
depression even before capnography is able to detect the 
decreasing expiratory carbon dioxide levels. 
There are also many opportunities for pharmacists to prevent 
respiratory depression and over-sedation events before they 
occur. High opioid doses were a contributing factor in 40% of 
over-sedation events in this study.  Although at times high 
opioid doses are necessary for opioid-tolerant patients 
Figure 2: Proposed 
scorecard. 
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experiencing intractable pain, careful pharmacist assessment 
is prudent in preventing an accidental overdose.  PCA usage is 
another area for pharmacists to be extra vigilant.  The use of 
a PCA with a basal rate in an opioid naïve patient was 
involved in 27% of over-sedation events in this study.  
Although PCA order sets specifically advise against this 
practice, it still sometimes occurs.  This is an area of 
opportunity for pharmacists to intervene on the patient’s 
behalf, verifying the patient’s use of opioids prior to admit, as 
well as educating physicians on the importance of reserving 
basal rates for opioid tolerant patients, until the need for a 
basal rate is otherwise demonstrated.  
There are several limitations to this research.  Most 
significant is the small sample size.  Our study was not 
adequately powered;  rather, the aim was to identify trends 
which could be useful to distinguish between patients.  
Additional studies examining a larger patient population 
would help to further guide the determination of the most 
important risk factors in the prediction of respiratory 
depression.  Additionally, since the scorecard generated by 
the results of this study has not been tested or validated, it 
should be seen as guide and not a diagnostic tool for identify 
the most at-risk patients.   
In conclusion, the results of this retrospective chart review 
seem to demonstrate that the most important risk factors in 
predicting those patients most at risk for respiratory 
depression are ASA score ≥ 3 and the concomitant use of 
multiple opioids or an opioid and another CNS-active 
sedative.  Further studies are warranted to support these 
results. At this time, however, giving extra consideration to 
patients with these two important risk factors is likely 
prudent to decide the best candidates for capnography. 
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Table 1: The National Coordinating Council for Medication Error Reporting 
 and Prevention Index for Categorizing Medication Errors 
 
Category Description 
A Circumstances or events that have the capacity to cause error. 
B An error occurred but the error did not reach the patient. 
C An error occurred that reached the patient but did not cause patient harm. 
D An error occurred that reached the patient and required monitoring to confirm that it resulted 
in no harm to the patient and/or required intervention to preclude harm. 
E An error occurred that may have contributed to or resulted in temporary harm to the patient 
and required intervention. 
F An error occurred that may have contributed to or resulted in temporary harm to the patient 
and required initial or prolonged hospitalization. 
G An error occurred that may have contributed to or resulted in permanent patient harm. 
H An error occurred that required intervention necessary to sustain life. 
I An error occurred that may have contributed to or resulted in the patient’s death. 
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Table 2: Frequency and percentage of each risk factor in our entire study population 
Risk Factor Number 
of 
Patients 
Total 
Number 
Patients 
Assessed 
Percentage 
Multiple CNS/Sedating Meds 
ASA≥3 
33 
21 
38 
28 
86% 
75% 
High Opioid Dose 
PCA Use 
Diagnosed Lung Disease 
16 
15 
14 
40 
40 
40 
40% 
37.5% 
35% 
Renal or Hepatic Insufficiency 
Dose Stacking 
14 
12 
40 
40 
35% 
30% 
Age≥65 11 40 27.5% 
PCA with Basal Rate in Opioid Naive 3 11 27% 
BMI≥35 10 37 27% 
Diagnosed Sleep Apnea  5 40 12.5% 
Muscular Disorder 4 40 10% 
Unstable PACU Transfer 2 40 5% 
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Table 3: The most commonly implicated medications in  
respiratory depression events in the study population 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Medication Number 
 Opioids 
Fentanyl IV bolus 15 
Hydromorphone PCA 13 
Hydromorphone IV bolus  11 
Oxycodone IR 6 
Morphine IV bolus 
Percocet 
Methadone 
Fentanyl patch 
Oxycontin 
Morphine PCA 
Norco 5/325 
4 
4 
4 
2 
2 
2 
1 
CNS-active sedatives 
Benzodiazepines 
Midazolam 
 
12 
Lorazepam 5 
Clonazepam  1 
Alprazolam 1 
First-generation H1 Antagonists 
Diphenhydramine 
Hydroxyzine 
Others 
Zolpidem 
 
5 
1 
 
2 
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Table 4: Frequency and percentage of each risk factor 
 in ‘average risk’ (3-4 risk factor) patients 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Risk Factor Number of 
Patients 
Total 
Number 
Patients 
Assessed 
Percentage 
Multiple CNS/Sedating Meds 
ASA≥3 
Dose Stacking 
PCA with Basal Rate in Opioid Naive 
17 
6 
9 
2 
20 
13 
20 
5 
85% 
46% 
45% 
40% 
High Opioid Dose 
Diagnosed Lung Disease 
Renal or Hepatic Insufficiency 
7 
7 
7 
20 
20 
20 
35% 
35% 
35% 
BMI≥35 5 19 26% 
PCA Use 5 20 25% 
Age≥65 5 20 25% 
Muscular Disorder  2 20 10% 
Unstable PACU Transfer 1 20 5% 
Diagnosed Sleep Apnea 0 20 0% 
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Figure 1: Proposed scorecard 
 
Scorecard for Assessing Respiratory 
Depression Risk: 
1. Give the patient one point for each of 
the following risk factors: 
-PCA use 
-PCA use with a basal rate in a opioid-
naïve patient 
-high opioid dose (>30mg oral 
morphine per day or equivalent) 
-diagnosed muscular disorder 
-diagnosed lung disease 
-diagnosed sleep apnea 
-renal or hepatic insufficiency 
-BMI ≥ 35 
-age ≥ 65 years 
 
2. Give the patient two points for each 
of the following risk factors: 
-ASA ≥ 3 
-concomitant use of multiple opioids or 
an opioid with another CNS-active 
sedative (such as a benzo, barbiturate, 
first generation H1 antagonist, or Z-
drug) 
 
3. Calculate the sum—the ‘risk factor 
equivalent’.  If it is five or greater, 
patient should be preferentially 
considered for capnography 
monitoring. 
